Due to safety concerns associated with some mask-based therapies for patients with heart failure and reduced left ventricular ejection fraction (LVEF), post-hoc analysis was performed on the heart failure cohort from the Pivotal Trial.
Patients with both heart failure and central sleep apnea comprise over half (68%) of patients studied in the remedē® System Pilot and Pivotal studies. In post-hoc analysis, the heart failure cohort demonstrated similar sleep and quality of life improvements to that of the full population.1,2
- Costanzo MR, et al. European Journal of Heart Failure 2018; doi:10.1002/ejhf.1312.
- Fudim M, Spector AR, Costanzo MR, et al. J Clin Sleep Med. 2019;15(12):17471755.
- Ponikowski P, et al. Eur J Heart Fail 2019;21 (S1): 346; doi:10.1002/ejhf.1488